Skip to main content

Brolucizumab ophthalmic

Generic name: brolucizumab ophthalmic [ BROE-lue-SIZ-ue-mab ]
Brand name: Beovu
Dosage form: intravitreal solution (dbll 6 mg/0.05 mL)
Drug class: Anti-angiogenic ophthalmic agents

Medically reviewed by on Oct 16, 2023. Written by Cerner Multum.

What is brolucizumab ophthalmic?

Brolucizumab is made from a human antibody fragment. It works by keeping new blood vessels from forming under the retina (a sensory membrane that lines the inside of the eye). In people with certain types of eye disorders, new blood vessels grow under the retina where they leak blood and fluid.

Brolucizumab ophthalmic (for the eyes) is used to treat the "wet form" of age-related macular degeneration.

Brolucizumab ophthalmic may also be used for purposes not listed in this medication guide.

Brolucizumab ophthalmic side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Brolucizumab ophthalmic may cause serious side effects. Call your doctor at once if you have:

Common side effects of brolucizumab ophthalmic may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Before taking this medicine

You should not use brolucizumab if you are allergic to it, or if you have:

Tell your doctor if you have ever had:

Do not use brolucizumab if you are pregnant. It could harm the unborn baby or cause birth defects. Use effective birth control to prevent pregnancy while you are receiving brolucizumab ophthalmic and for at least 1 month after your last dose.

Do not breastfeed while receiving this medicine, and for at least 1 month after your last dose.

How is brolucizumab ophthalmic given?

Brolucizumab is given as an injection into your eye. Your doctor will use a medicine to numb your eye before giving you the injection. You will receive this injection in your doctor's office or other clinic setting.

For a short time after your injection, your eyes will be checked periodically to make sure the injection has not caused any side effects.

Brolucizumab is usually given once per month for 3 months, and then once every 8 to 12 weeks.

Follow your doctor's dosing instructions very carefully. The timing of your monthly injections is very important for this medication to be effective.

Brolucizumab ophthalmic dosing information

Usual Adult Dose for Macular Degeneration:

Initial dose: 6 mg by intravitreal injection once a month for the first 3 doses
Maintenance dose: 6 mg by intravitreal injection once every 8 to 12 weeks

-This drug should be administered by a qualified physician.
-Once monthly injections should be administered approximately every 25 to 31 days.
-In clinical trials, the maintenance dosing interval was guided by visual and anatomical measures of disease activity; the utility of these measures has not been established.

Use: For the treatment of neovascular (wet) age-related macular degeneration (AMD).

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your brolucizumab injection.

What happens if I overdose?

Since brolucizumab ophthalmic is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

What should I avoid while receiving brolucizumab ophthalmic?

This medicine may cause blurred vision and may impair your reactions. Avoid driving or hazardous activity until you know how this medicine will affect you.

What other drugs will affect brolucizumab ophthalmic?

Medicine used in the eyes is not likely to be affected by other drugs you use. But many drugs can interact with each other. Tell each of your healthcare providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.

Popular FAQ

Beovu (brolucizumab-dbll) is used to treat wet AMD (age-related macular degeneration) in adults. Two trials (HAWK and Harrier) have reported the benefits with Beovu are similar to those seen with Eylea. Improvements in visual acuity (the ability to see more clearly) started after the first injection of Beovu and were noticeable within 4 weeks, reached their maximum at 48 weeks, and persisted for at least 2 years (the length of the trial). Continue reading

More FAQ

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.